Ascletis Pharma Inc.

Investors

Voluntary Announcement - Proposed Share Repurchase under the Repurchase Mandate
2020-09-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2020
2020-09-04
2020 Interim Results
2020-08-28
Voluntary Announcement - Completion of Bridging Study of ASC18
2020-08-20
Voluntary Announcement - First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, A Subcutaneously Administered PD-L1 Antibody
2020-08-17
Notice of Board Meeting
2020-08-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2020
2020-08-05
Voluntary Announcement - Approval for Marketing All-oral HCV Treatment
2020-07-31
Voluntary Announcement - Bridging Study in China Completed for NASH Drug Candidate ASC40
2020-07-20
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2020
2020-07-03

4

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备 11050387号